PCI Biotech and Ultimovacs initiates preclinical research collaboration NewsKristin EivindvikJanuary 27, 2016
Dose escalation in the bile duct cancer study completed with promising early signs of efficacy NewsKristin EivindvikJanuary 22, 2016
Mandatory notification of trade - employee share option scheme NewsKristin EivindvikNovember 30, 2015
PCI Biotech strengthens the organisation by appointing world leading experts to inaugural Scientific Advisory Committee NewsKristin EivindvikOctober 16, 2015
PCI Biotech to present at the Oligonucleotide Therapeutics Society (OTS) 11th Annual Meeting NewsKristin EivindvikOctober 13, 2015
Presentation of PCI Biotech’s bile duct study at the annual German Gastroenterology Congress 2015 NewsKristin EivindvikSeptember 18, 2015
PCI Biotech signs pre-clinical research collaboration agreement with a top-10 large pharma company NewsKristin EivindvikSeptember 10, 2015
PCI Biotech announces activation of Oslo University Hospital as a new clinical site NewsKristin EivindvikAugust 31, 2015
Successful completion of the third dose cohort in the study for patients with inoperable bile duct cancer NewsKristin EivindvikAugust 18, 2015
PCI Biotech: Presentation of second quarter and first-half year 2015 results NewsKristin EivindvikAugust 6, 2015
